Following $105M raise, St. Louis biotech startup Arch Oncology adds 3 execs to C-suite

The St. Louis biotech startup has bolstered its medical and clinical leadership as the company advances development of its lead drug candidate.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.